NCT00316992 - Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Ramelteon and Placebo

Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.

Trial Locations (8)

New York

St. Petersburg

Naples

Birmingham

Louisville

Lincoln

Santa Monica

Los Angeles